Immunotherapeutic agents

Details Immunotherapeutic agents Immunotherapeutic agents

2006-03-28

2006-03-28

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S402000

Reexamination Certificate

active

07019030

ABSTRACT:
Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor α, nuclear factor κB, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4492708 (1985-01-01), Spitzer
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5135940 (1992-08-01), Belanger et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5414008 (1995-05-01), Muller et al.
patent: 5463063 (1995-10-01), Muller
patent: 5580888 (1996-12-01), Warrellow et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5605914 (1997-02-01), Muller
patent: 5632984 (1997-05-01), Wong et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller
patent: 5728844 (1998-03-01), Muller
patent: 5728845 (1998-03-01), Muller
patent: 5733566 (1998-03-01), Lewis
patent: 5736570 (1998-04-01), Muller
patent: 5770589 (1998-06-01), Billson
patent: 5801195 (1998-09-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6001368 (1999-12-01), Jenks
patent: 6011050 (2000-01-01), Muller et al.
patent: 6015803 (2000-01-01), Wirostko
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6075041 (2000-06-01), Muller
patent: 6130226 (2000-10-01), Muller et al.
patent: 6180644 (2001-01-01), Muller et al.
patent: 6200987 (2001-03-01), Muller
patent: 6214857 (2001-04-01), Muller et al.
patent: 6218369 (2001-04-01), Bombardelli et al.
patent: 6225348 (2001-05-01), Paulson
patent: 6262101 (2001-07-01), Muller et al.
patent: 6284780 (2001-09-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6429221 (2002-08-01), Muller et al.
patent: 6479554 (2002-11-01), Muller et al.
patent: 6518281 (2003-02-01), Muller et al.
patent: 6656964 (2003-12-01), Muller et al.
patent: 6667316 (2003-12-01), Man et al.
patent: 6699899 (2004-03-01), Man et al.
patent: 6844359 (2005-01-01), Muller et al.
patent: 2001/0056107 (2001-12-01), Muller et al.
patent: 2003/0045726 (2003-03-01), Muller et al.
patent: 2003/0187052 (2003-10-01), Muller et al.
patent: 2004/0006096 (2004-01-01), Muller et al.
patent: 2004/0019106 (2004-01-01), Muller et al.
patent: 2004/0147588 (2004-07-01), Man et al.
patent: 2004/0167174 (2004-08-01), Man et al.
patent: 2004/0167199 (2004-08-01), Muller et al.
patent: 2004/0204448 (2004-10-01), Man et al.
patent: 2004/0254214 (2004-12-01), Muller et al.
patent: 2004/0259873 (2004-12-01), Man et al.
patent: 2005/0014727 (2005-01-01), Muller et al.
patent: 35 25 623 (1987-01-01), None
patent: 42 20 983 (1994-01-01), None
patent: 0091795 (1983-10-01), None
patent: 0316594 (1989-05-01), None
patent: 0 395 446 (1990-10-01), None
patent: 0 626 957 (1994-07-01), None
patent: 44-26659 (1969-07-01), None
patent: 58188868 (1983-11-01), None
patent: 05066591 (1993-03-01), None
patent: 74/04800 (1994-07-01), None
patent: 94/14742 (1994-07-01), None
patent: 94/20455 (1994-09-01), None
patent: WO 95/01348 (1995-01-01), None
patent: 96/20926 (1996-07-01), None
patent: 96/21435 (1996-07-01), None
patent: WO 97/08143 (1997-03-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 98/06692 (1998-02-01), None
patent: WO 99/06041 (1999-02-01), None
patent: WO 00/01387 (2000-01-01), None
patent: WO 01/34606 (2001-05-01), None
patent: WO 01/45702 (2001-06-01), None
patent: WO 03/080048 (2003-10-01), None
patent: WO 03/080049 (2003-10-01), None
Groundwater et al., Electrocyclic Aromatic Substitution by Nitrile Ylides to give 3H-2-benzazepines: Substituent Effects and Mechanism, Tetrahedron, vol. 48, No. 37, pp. 7951-7964, (1992).
R.W. Guthrie, et al., “Pentadienyl Carboxamide Derivatives as Antagonists of Platelet-Activating Factor”, Journal of Medicinal Chemistry, vol. 32, No. 8, pp. 1820-1835 (1989) Chem. SQ 8924.503.
A. Shigehiro, et al., “Beta-Acryicinnamitriles”, Chemical Abstracts, vol. 72 (5), (1970), Abstract 21510t.
Erikson, M., et al., “Gaschromatographische Analye von Liginoxydationsprodukten.VII. Ein verbessertes Verfahren zur Charakterierung von Ligninen durch Methylierung und oxydativen Abbau”, ACTA Chemica Scandinavica, vol. 27 (1), 1973, pp. 127-140 compounds 40-46, p. 134 (not translated).
Zarubia, M.Y., et al., “Acid-base reactions to lignin with strong acids”, Chemical Abstracts, vol. 83 (14), 1975, Abs. Khin & Dev., vol. 3 (1975) 117388n.
Mamadzhanov, A., et al., “Condensation of pyrocathecol and its methyl ethers with alpha-phenylbenzyl alcohols in the presense of polyphosphoric acid”, Chemical Abstracts, vol. 94 (25), (1981), 208463b.
Koch, H.P., et al., “Thalidomide and Congeners as Anti-inflammatory Agents”, Progress in Medicinal Chemistry, vol. 22, (1985), pp. 165-242.
Ghassan S. Dbaibo, et al., “Tumor Necrosis Factor-alpha (TNF-alpha) Signal Transduction through Ceramide”, The Journal of Biological Chemistry, vol. 268, No. 24, Aug. Issue, pp. 17762-17766 (1993).
Yuichiro J. Suzuki, et al., “Inhibition of NF-kB activation by vitamin E derivatives”, Biochemical and Biophysical Research Communications, vol. 193, No. 1, (May 1993), pp. 277-283.
Guido Poli, et al., “The Effect of Cytokines and Pharmacologic Agents on Chronic HIV Infection”, AIDS Research and Human Retroviruses, vol. 8, No. 2, (1992), pp. 191-197.
F. Bachelerie, et al., “HIV enhancer activity perpetuated by NF-kB induction on infection of monocytes”, Letters to Nature, vol. 350, (Apr. 1991), pp. 709-712.
S. Joseph Leibovich, et al., “Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha”, Letters to Nature, vol. 329, (Oct. 1987), pp. 630-632.
Michael J. Lenardo, et al., “NF-kB: A Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control”, Cell., vol. 58, (Jul. 1989), pp. 227-229.
Kevin J. Tracey, et al., “Shock and Tissue Injury Induced by Recombinant Human Cachectin”, Science, vol. 234, pp. 470-474, (1986).
L.B. Hinshaw, et al., “Survival of Primates in LD 100 Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNF-alpha)”, Circulatory Shock, 30, (1990), pp. 279-292.
L-M Ching, et al., “Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid”, British Journal of Cancer, (1995), 72, pp. 339-343.
N. B. Vedder, et al., “Inhibition of Leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear”, Proc. Natl. Acad. Sci. USA, vol. 87 (Apr. 1990), pp. 2643-2646.
Thomas M. Folks, et al., “Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone”, Proc. Natl., Acad. Sci. USA, vol. 86, (Apr. 1989), pp. 2365-2368.
Kathleen A. Clouse, et al., “Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infected Human T Cell Clone”, The Journal of Immunology, vol. 142, No. 2, (Jan. 1989), pp. 431-438.
Kathleen A. Clouse, et al., “Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infected Human T Cell Clone”, The Journal of Immunology, vol. 142, No. 2, (Jan. 1989), pp. 431-438.
Susan C. Wright, et al., “Spontaneous Cytotoxicity and Tumor Necrosis Factor Production By Peripheral Blood Monocytes From AIDS Patients”, The Journal

Affiliated with

Also associated with

Rating

Immunotherapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3597369